Equity Details
Price & Market Data
Price: $67.21
Daily Change: -$2.77 / 4.12%
Daily Range: $65.97 - $73.00
Market Cap: $218,114,656
Daily Volume: 21,637
Performance Metrics
1 Week: -8.89%
1 Month: -9.68%
3 Months: 3.40%
6 Months: 119.4%
1 Year: 796.1%
YTD: 59.49%
About Sol-Gel Technologies Ltd. (SLGL)
Get up-to-date information on Sol-Gel Technologies Ltd. (SLGL). The stock is trading at 67.21, with a daily performance indicating a change of -$2.77 / 4.12%. Its market cap is recorded at 218,114,656. Delve into detailed performance metrics, from short-term (1-week) to long-term (1-year) and year-to-date returns.
Company Details
Employees: 28
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.